0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > Integrin alpha L beta 2 > IT2-H53W3

Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free

  • Synonym
    Integrin alpha L beta 2,ITGAL&ITGB2
  • Source
    Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (IT2-H53W3) is expressed from CHO cells. It contains AA Tyr 26 - Met 1089 (ITGAL) & Gln 23 - Asn 700 (ITGB2) (Accession # P20701-1(ITGAL) & P05107-1(ITGB2)).
    Predicted N-terminus: Tyr 26 (ITGAL) & Gln 23 (ITGB2)
  • Molecular Characterization
    Online(Tyr 26 - Met 1089 (ITGAL) & Gln 23 - Asn 700 (ITGB2)) P20701-1 (ITGAL) & P05107-1 (ITGB2)

    Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAL and ITGB2, has a calculated MW of 124.1 kDa (ITGAL) & 80.2 kDa (ITGB2). Subunit ITGAL is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and subunit ITGB2 contains no tag but a basic tail at the C-terminus. The protein migrates as 140-150 kDa (ITGAL) and 90-95 kDa (ITGB2) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by reduced SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) SDS-PAGE gel

Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag FreeHuman ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) ELISA bioactivity

Immobilized Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) at 10 μg/mL (100 μL/well) can bind Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) with a linear range of 0.4-6 ng/mL (QC tested).

Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag FreeHuman ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) ELISA bioactivity

Immobilized Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) at 10 μg/mL (100 μL/well) can bind Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) with a linear range of 0.156-5 μg/mL (Routinely tested).

  • Background
    Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $410.00

Price(USD) : $2880.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:0 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop